Dr. John Cush RheumNow
2 years 9 months ago
2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ?
Top 5 specialties rechosen:
Cardiology: 82% & Dermatology: 82%
Psychiatry: 81%
Allergy and immunology: 80%
Neurology: 79%
Rheumatology: 78% https://t.co/Zy4AJzb7dn. https://t.co/m9HjQ4T5aW
Dr. John Cush RheumNow
2 years 9 months ago
Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/xLxvPCsRC9 https://t.co/mWwo7GgCIq
Dr. John Cush RheumNow
2 years 9 months ago
Biologics, #RA and Risk of skin CA (NMSC) is complex.
- RA alone is a risk for NMSC
49K study of ABA & NMSC ;
- In RCTs, risk same w/ ABA & PBO
- Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs
- Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc
A study of nearly 80,000 US veterans who underwent primary knee joint arthroplasty (TKA) showed the incidence of prosthetic joint infection (PJI) was highest in the first 3 months and remained elevated through 12 months compared with 12 months or more after surgery. Gram-negative organisms were more prevalent in early vs delayed or late PJIs.
I recently overheard a very good practicing rheumatologist complain, “why do I need yet another drug for psoriatic arthritis? I have more treatment choices than I have actual PsA patients who need a new or better drug”.
Dr. John Cush RheumNow
2 years 9 months ago
UK biobank population study shows a bidirectional assoc. betw RA & ILD (each @ incr risk for the other). In non-COPD pts, RA increased risk of COPD (HR=1.65) & in non-RA pts, COPD had a higher risk of future RA (HR=1.67). Both mediated by inflammation https://t.co/imn4ddV7CS https://t.co/UZaszEnCqt
Dr. John Cush RheumNow
2 years 9 months ago
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/ACe7nDDwop https://t.co/lV66WerkAp
Dr. John Cush RheumNow
2 years 9 months ago
PMR QD Clinics - Teaching Cases
https://t.co/fJThsc2T2k https://t.co/c4mAVqfBeO
Dr. John Cush RheumNow
2 years 9 months ago
Late Should Not Be Less
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow .
https://t.co/GwJdJKHuDZ https://t.co/S51g7aQ0i4
Dr. John Cush RheumNow
2 years 9 months ago
RheumNow will be providing #ACR23 coverage from Nov 11-15. Tune in for daily recaps, KOL videos, live streaming and more. https://t.co/2kBkHq6rIc
Dr. John Cush RheumNow
2 years 9 months ago
LANCET: Efgartigimod (neonatal Fc receptor mAb) shown effective in chronic #ITP. RCT, 205 pts with refractory ITP (Plt <30K for ~10.6 yrs) Rx w/ EFGR vs PBO. @24 wks EFGR incr Plt >50k in 22% vs. 6%). A larger RCT in progress https://t.co/uXyjYoXlyF https://t.co/jGroGNeD4W
Dr. John Cush RheumNow
2 years 9 months ago
Marijuana use is on the rise, including older adults. Data presented at 2023 AHA (cardiology) meeting suggests that marijuana user have higher risk of MI & CVA; & daily marijuana users were 34% more likely to develop heart failure (in hospitalized adults) https://t.co/EnEnf6pqdr https://t.co/GXSv30AFLr
Dr. John Cush RheumNow
2 years 9 months ago
NEJM: Clinical Examination of the Cervical Spine (full read, with video). Great overview of Cx exam, useful in evaluation of axial neck pain, radiculopathy, or myelopathy; info on dermatomes, reflexes, Lhermites sign, etc https://t.co/EMizgh6Dtg https://t.co/6tdx1LBSDh
The American College of Rheumatology (ACR) expressed concern that the conversion factor included in the Centers for Medicare and Medicaid Services (CMS) CY 2024 Medicare Physician Fee Schedule and Quality Payment Program final rule is insufficient to address rising inflation.
